Bacterial Pneumonia Global Market Report 2025

The bacterial pneumonia market size has grown strongly in recent years. It will grow from $2.31 billion in 2024 to $2.52 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to increased awareness of respiratory diseases, a higher prevalence of bacterial infections, a growing geriatric population, increased healthcare expenditure, rapid urbanization, and rising air pollution levels.

The bacterial pneumonia market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period is driven by rising tobacco and alcohol consumption, increased government initiatives and funding, a growing prevalence of respiratory infections, rising antibiotic resistance, expanded healthcare access, greater awareness of bacterial pneumonia, and advancements in novel therapeutics and vaccines. Key trends include the development of innovative antibiotics, adoption of rapid diagnostic tools, advancements in vaccine technology, emergence of personalized medicine, integration of AI in disease management, and expanded use of monoclonal antibodies.

The increasing prevalence of respiratory diseases is anticipated to drive the growth of the bacterial pneumonia market. Respiratory diseases encompass medical conditions that disrupt breathing and gas exchange by affecting the organs and tissues of the lungs and airway systems. Several factors contribute to the rising incidence of respiratory diseases, including environmental, lifestyle, demographic, and genetic influences. These conditions heighten susceptibility to bacterial pneumonia by weakening the immune system and damaging lung tissues, thereby creating a favorable environment for bacterial infections. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported an increase in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. Consequently, the growing prevalence of respiratory diseases is fueling the expansion of the bacterial pneumonia market.

Leading companies in the bacterial pneumonia market are emphasizing innovations in vaccine technology, such as the development of conjugate vaccines, to enhance immune response, improve efficacy, and offer broader protection against multiple bacterial strains. Conjugate vaccines work by linking a weak antigen to a carrier protein to effectively boost immunity. For instance, in June 2024, Merck & Co. Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine). This vaccine is designed to prevent invasive pneumococcal disease and pneumonia caused by various serotypes of Streptococcus pneumoniae, specifically targeting adults aged 18 and older. The introduction of this vaccine plays a crucial role in combating bacterial pneumonia and related pneumococcal infections.

In August 2022, GlaxoSmithKline plc, a UK-based pharmaceutical company, acquired Affinivax Inc. for $2.1 billion. Through this acquisition, GSK aims to strengthen its vaccine research and development by leveraging Affinivax's MAPS technology to create next-generation pneumococcal vaccines with expanded coverage and enhanced immunity. This advancement seeks to address unmet needs in bacterial pneumonia prevention. Affinivax Inc. is a US-based biotechnology company specializing in the development of vaccines for respiratory conditions.

Major players in the bacterial pneumonia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, GSK plc, bioMerieux SA, Shionogi & Co. Ltd., Wockhardt Limited., Zai Lab Limited, Innoviva Inc., Eagle Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc., Clarametyx Biosciences Inc., Evopoint Biosciences Inc., Vaxcyte Inc., and Acurx Pharmaceuticals Inc.

North America was the largest region in the bacterial pneumonia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bacterial pneumonia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bacterial pneumonia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bacterial pneumonia is a severe and potentially life-threatening respiratory condition caused by bacterial infections. It leads to inflammation and the accumulation of fluid or pus in the alveoli of the lungs, which disrupts normal oxygen exchange. This results in symptoms such as a severe cough, difficulty breathing, fever, chills, and chest pain, necessitating prompt medical intervention and appropriate treatment.

The primary types of bacterial pneumonia include community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). Community-acquired pneumonia (CAP) is a lung infection that develops outside healthcare settings and is typically caused by bacteria, viruses, or fungi, leading to lung inflammation and impaired gas exchange. Treatments are administered through oral, subcutaneous, or other methods and include vaccines and medications. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The bacterial pneumonia market research report is one of a series of new reports that provides bacterial pneumonia market statistics, including the bacterial pneumonia industry's global market size, regional shares, competitors with a bacterial pneumonia market share, detailed bacterial pneumonia market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial pneumonia industry. This bacterial pneumonia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bacterial pneumonia market includes revenues earned by entities by providing services such as chest X-rays and computed tomography (CT) scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial pneumonia market consists of sales of broad-spectrum antibiotics, narrow-spectrum antibiotics, pneumococcal vaccines, mechanical ventilators, cough suppressants, and expectorants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.